RHYTHM PHARMACEUTICALS, INC. — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Next earnings (estimated): Wed, April 1, 2026 — 30 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | $57M | ↑+36.9% | — | — | — |
| 2025-09-30 | $51M | ↑+54.3% | $-53M | ↓-21.2% | -102.6% |
| 2025-06-30 | $49M | ↑+66.8% | $-47M | ↓-44.5% | -93.4% |
| 2025-03-31 | $33M | ↑+25.9% | $-49M | ↑+65.0% | -143.7% |
| 2024-12-31 | $42M | ↑+72.6% | — | — | — |
| 2024-09-30 | $33M | ↑+47.8% | $-44M | ↑+1.2% | -132.0% |
| 2024-06-30 | $29M | ↑+51.3% | $-32M | ↑+30.9% | -139.2% |
| 2024-03-31 | $26M | ↑+126.4% | $-141M | ↓-170.9% | -538.7% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q4)
Revenue
$57M
↑+36.9% +$15M YoY
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Go deeper
RYTM Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyRYTM Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics